• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by agilon health inc. (Amendment)

    2/9/24 8:35:54 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care
    Get the next $AGL alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 AGILON HEALTH INC COMMON STOCK Cusip #00857U107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00857U107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 60,724,095 Item 6: 0 Item 7: 60,782,728 Item 8: 0 Item 9: 60,782,728 Item 11: 14.969% Item 12: HC Cusip #00857U107 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 60,782,728 Item 8: 0 Item 9: 60,782,728 Item 11: 14.969% Item 12: IN Item 1(a). Name of Issuer: AGILON HEALTH INC Item 1(b). Address of Issuer's Principal Executive Offices: 6210 E HWY 290, Suite 450 Austin, TX 78723 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 00857U107 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 60,782,728 (b) Percent of Class: 14.969% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 60,782,728 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of AGILON HEALTH INC. No one other person's interest in the COMMON STOCK of AGILON HEALTH INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of AGILON HEALTH INC at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $AGL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGL

    DatePrice TargetRatingAnalyst
    8/20/2025$1.40Outperform → Mkt Perform
    Bernstein
    8/6/2025$1.00Buy → Neutral
    Citigroup
    4/25/2025$5.00Neutral → Buy
    Citigroup
    4/8/2025$8.50Mkt Perform → Outperform
    Bernstein
    1/10/2025$1.75 → $2.25Sell → Neutral
    Citigroup
    1/10/2025Hold
    Needham
    12/16/2024Neutral
    Macquarie
    12/11/2024$2.50Mkt Perform
    Bernstein
    More analyst ratings

    $AGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Agilon Health downgraded by Bernstein with a new price target

    Bernstein downgraded Agilon Health from Outperform to Mkt Perform and set a new price target of $1.40

    8/20/25 8:21:47 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Agilon Health downgraded by Citigroup with a new price target

    Citigroup downgraded Agilon Health from Buy to Neutral and set a new price target of $1.00

    8/6/25 7:57:52 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Agilon Health upgraded by Citigroup with a new price target

    Citigroup upgraded Agilon Health from Neutral to Buy and set a new price target of $5.00

    4/25/25 8:23:09 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

    SCHEDULE 13G/A - agilon health, inc. (0001831097) (Subject)

    9/5/25 5:41:23 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SCHEDULE 13G filed by agilon health inc.

    SCHEDULE 13G - agilon health, inc. (0001831097) (Subject)

    8/29/25 11:00:27 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

    SCHEDULE 13G/A - agilon health, inc. (0001831097) (Subject)

    8/13/25 12:56:59 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Schwaneke Jeffrey A. bought $250,206 worth of shares (22,300 units at $11.22) and was granted 428,922 shares, increasing direct ownership by 61% to 1,130,552 units (SEC Form 4)

    4/A - agilon health, inc. (0001831097) (Issuer)

    4/3/25 7:40:25 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    CEO & President Sell Steven covered exercise/tax liability with 15,563 shares and bought 42,426 shares, increasing direct ownership by 8% to 355,310 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    3/18/25 6:42:37 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Chief Markets Officer Shaker Benjamin bought 11,786 shares and covered exercise/tax liability with 4,143 shares, increasing direct ownership by 2% to 457,058 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    3/18/25 6:41:48 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    agilon health Sets Date to Report Third Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 291396. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the call will be availabl

    10/6/25 4:12:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health to Participate in the 2025 Jefferies Healthcare Services Conference

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that its management team will participate in a fireside chat at the 2025 Jefferies Healthcare Services Conference on Tuesday, September 30 at 8:45am ET. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the "Events & Presentations" section of agilon health's investor relations website at https://investors.agilonhealth.com. Replays will be available for on-demand listening shortly after the completion of the presentation. About agilon health agilon health is the trusted partner empowering physici

    9/16/25 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Announces Leadership Transition

    Steven Sell steps down as President, Chief Executive Officer, and Board Director Ronald A. Williams, co-founder, Board Chairman, and healthcare industry veteran, appointed Executive Chairman Board establishes an Office of the Chairman and initiates search for permanent CEO Company reports second quarter 2025 earnings and withdraws full year 2025 guidance agilon health (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Steven Sell has stepped down as President, CEO, and a Director of the Board. Ronald A. Williams, the Company's co-founder and Board Chairman since 2017, has been appointed Executive Chairman. Williams

    8/4/25 4:10:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Gertsch Timothy covered exercise/tax liability with 406 shares, decreasing direct ownership by 0.35% to 114,752 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    8/19/25 5:39:24 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Chief Legal Officer Zamore Denise covered exercise/tax liability with 915 shares, decreasing direct ownership by 0.21% to 443,125 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    8/5/25 5:10:48 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Chief Financial Officer Schwaneke Jeffrey A. covered exercise/tax liability with 46,099 shares, decreasing direct ownership by 4% to 1,075,122 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    7/3/25 4:08:23 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Leadership Updates

    Live Leadership Updates

    View All

    agilon health Announces Leadership Transition

    Steven Sell steps down as President, Chief Executive Officer, and Board Director Ronald A. Williams, co-founder, Board Chairman, and healthcare industry veteran, appointed Executive Chairman Board establishes an Office of the Chairman and initiates search for permanent CEO Company reports second quarter 2025 earnings and withdraws full year 2025 guidance agilon health (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Steven Sell has stepped down as President, CEO, and a Director of the Board. Ronald A. Williams, the Company's co-founder and Board Chairman since 2017, has been appointed Executive Chairman. Williams

    8/4/25 4:10:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Appoints Karthik Rao, M.D., as Chief Medical Officer

    Dr. Rao to Continue to Lead Clinical Strategy and Drive Physician Network Performance Alongside agilon's Chief Clinical Officer Kevin Spencer, M.D. agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that after a comprehensive search Karthik Rao, M.D., who has served as agilon's interim chief medical officer (CMO) since February 2024, has been appointed to the permanent CMO role, effective immediately. He previously served as senior medical director and vice president, network performance, at the company. Prior to joining agilon in 2022, Dr. Rao held several roles in value-based care, including nearly a d

    7/10/24 8:00:00 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Names Jeff Schwaneke New Chief Financial Officer

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Jeff Schwaneke, an experienced finance, operational and managed care executive and director on agilon's board, will join the Company as chief financial officer and executive vice president effective July 1, 2024. He will be a member of agilon's Executive Leadership team reporting to chief executive officer (CEO), Steve Sell. Schwaneke succeeds Timothy Bensley, who announced his retirement from agilon in early 2024. Bensley has agreed to stay on through a transition period. Schwaneke was most recently executive vice president, Health Care Enterprises,

    6/5/24 8:00:00 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Financials

    Live finance-specific insights

    View All

    agilon health Sets Date to Report Third Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 291396. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the call will be availabl

    10/6/25 4:12:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Sets Date to Report Second Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the second quarter 2025 after the market closes on Tuesday, August 5, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 938716. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of t

    7/22/25 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Sets Date to Report First Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the first quarter 2025 after the market closes on Tuesday, May 6, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 095319. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the ca

    3/25/25 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by agilon health inc.

    SC 13G/A - agilon health, inc. (0001831097) (Subject)

    11/13/24 12:49:26 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by agilon health inc.

    SC 13G/A - agilon health, inc. (0001831097) (Subject)

    11/8/24 10:52:39 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by agilon health inc.

    SC 13G/A - agilon health, inc. (0001831097) (Subject)

    11/6/24 4:47:14 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care